Fadini GP, et al. - Since accumulated evidence shows that cardiovascular events (CVEs) were avoided using some glucose-lowering medications in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease, researchers assessed whether and how glucose-lowering medication prescription pattern changes in T2DM following a CVE in a retrospective multicenter study-the Diabetes Therapy After a Cardiovascular Event (DATAFILE)- performed in Italy. The prescription of beta-blockers, loop diuretics, dual antiplatelet therapy was significantly increased and that of metformin was significantly reduced, following a median of 9.5 months, in patients with vs without a CVE. In T2DM patients, CVE occurrence did not prime the prescription of glucose-lowering medications provided with cardiovascular protective impacts, even though glucose control continued to be poor. Based on these findings, the therapeutic regimen of T2DM patients with established cardiovascular disease is required to be optimized, according to updated guidelines.